Prevalencia de diabetes y diabetes oculta en adultos de Castilla-La Mancha

Muiña, Patricio Giralt; Ávila, Gonzalo Gutiérrez; Herrera, M; Romero, Francisco Botella; Donado, J.J. Angulo

doi:10.1016/j.medcli.2010.11.019

Cited by 9 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship with the CRG patient classification system, a clear trend in the increase of pharmaceutical consumption was observed with the more serious health states. In the case of the analyzed population, multimorbidity was present in nearly all cases, which is consistent with the results of other studies [ 3 , 16 , 24 , 27 , 28 ] and similar to that of Giralt [ 29 ].…”

Section: Discussionsupporting

confidence: 92%

Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data

Sancho-Mestre

Vivas-Consuelo

Alvis-Estrada

et al. 2016

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundThe objective of the study is to estimate the frequency of multimorbidity in type 2 diabetes patients classified by health statuses in a European region and to determine the impact on pharmaceutical expenditure.MethodsCross-sectional study of the inhabitants of a southeastern European region with a population of 5,150,054, using data extracted from Electronic Health Records for 2012. 491,854 diabetic individuals were identified and selected through clinical codes, Clinical Risk Groups and diabetes treatment and/or blood glucose reagent strips. Patients with type 1 diabetes and gestational diabetes were excluded. All measurements were obtained at individual level. The prevalence of common chronic diseases and co-occurrence of diseases was established using factorial analysis.ResultsThe estimated prevalence of diabetes was 9.6 %, with nearly 70 % of diabetic patients suffering from more than two comorbidities. The most frequent of these was hypertension, which for the groups of patients in Clinical Risk Groups (CRG) 6 and 7 was 84.3 % and 97.1 % respectively. Regarding age, elderly patients have more probability of suffering complications than younger people. Moreover, women suffer complications more frequently than men, except for retinopathy, which is more common in males. The highest use of insulins, oral antidiabetics (OAD) and combinations was found in diabetic patients who also suffered cardiovascular disease and neoplasms. The average cost for insulin was 153€ and that of OADs 306€. Regarding total pharmaceutical cost, the greatest consumers were patients with comorbidities of respiratory illness and neoplasms, with respective average costs of 2,034.2€ and 1,886.9€.ConclusionsDiabetes is characterized by the co-occurrence of other diseases, which has implications for disease management and leads to a considerable increase in consumption of medicines for this pathology and, as such, pharmaceutical expenditure.

show abstract

Section: Discussionsupporting

confidence: 92%

Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data

Sancho-Mestre

Vivas-Consuelo

Alvis-Estrada

et al. 2016

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…Longitudinal data bases (questionnaires or administrative data bases) allow for an analysis of not only the loss in quality of life but the differences in life expectancy between diabetic and non-diabetic population, while controlling for other risk factors and diagnosed vascular disease, for the purpose of calculating the Adjusted Life years for diabetic and non-diabetic persons [44-46]. Secondly, body mass index (BMI) was calculated based on self-reported data on height and weight provided by survey respondents, thereby making responses susceptible to potential bias inherent in how respondents perceive themselves [47-50]. Similarly, there may be people with diabetes who have not been diagnosed with the disease.…”

Section: Discussionmentioning

confidence: 99%

Health- related quality of life in diabetic people with different vascular risk

2012

View full text Add to dashboard Cite

BackgroundThe number of papers on the health related quality of life of patients with DM has grown in recent years but fewer studies have drawn comparisons between diabetic persons and the general population considering different risk groups. The aim of this study is to examine health related quality of life (HRQOL) in people with diabetes mellitus (DM) and to analyze the differences in HRQOL adjusting by vascular risk.MethodsThe data used in this analysis was obtained from the responses of 15,926 individuals who participated in the 2006 Catalonia Health Survey. Our analysis provides a number of multivariate statistical models designed for studying HRQOL, based on the EQ-5D questionnaire, controlling for demographic factors of survey participants and variables that identify diagnosed illnesses and health problems.ResultsOur findings suggest there is a significant, moderate negative relationship between DM and HRQOL in comparison with non diabetic people (absolute value of the coefficient ranges between −0.04 and −0.054 points on a scale of 1). A further analysis of subgroups reveals that diabetics who have not had vascular risk factors neither vascular diseases do not have a diminished HRQOL when compared to the non-diabetic population in general, when other factors are controlled for. In contrast, a comparison of diabetics and non-diabetics who exhibit vascular disease or risk factors for vascular disease reveals HRQOL is significantly diminished to a greater extent for those with diabetes (between 0.152 and 0.175 points loss when comparing a non-diabetic person with a diabetic with vascular disease). Also, HRQOL in diabetic patients who have additional risk factors or a vascular disease are lower than people non-diabetic who have additional risk factors or a vascular disease. When we focus our analysis to the EQ-5D dimensions, we observe that diabetic persons who are neither at risk for nor have a diagnosed vascular disease are no more likely than non-diabetics to report problems. However, diabetic patients who have additional risk factors for vascular disease or a diagnosed vascular disease are significantly more likely to report moderated or severe problems in 4 of the 5 dimensions of EQ-5D.ConclusionsThe HRQOL of a person who has diabetes is not necessarily lower than for a non-diabetic. Control of risk factors associated to vascular diseases is a key factor for an enhanced quality of life. Vascular disease or risk factors for vascular disease, on the other hand, are associated with a significantly diminished quality of life for diabetic persons.

show abstract

“…In this study, the observed prevalence of T2D (10.8%, 2015) was comparable to that of the overall population in Spain (13.8%, 2010) [3], and the mean age of the patients was also similar (67.8 versus 65.5 years). The higher prevalence in men than in women (up to 74 years of age) has also been observed at the national level [5], suggesting that the included cohort could be representative of the national population with T2D.…”

Section: Discussionmentioning

confidence: 62%

“…(3) single minor chronic disease; (4) minor chronic disease in multiple organ systems; (5) single moderate dominant or chronic disease; (6) significant chronic disease in multiple organ systems; (7) dominant chronic disease in three or more organ systems; (8) dominant neoplasms, metastases and complications, and 9) severe diseases or extreme healthcare needs.…”

Section: Methodsmentioning

confidence: 99%

“…Type 2 diabetes (T2D) is the most common type of diabetes, accounting for around 90% of all diabetes cases [1]. The prevalence of T2D increases with age [4] and is higher in men than in women up to 74 years of age, after which this relationship is reversed [5]. Patients with T2D have an increased risk for macro-and microvascular diseases such as coronary heart disease, peripheral arterial disease, cerebrovascular accident, retinopathy, chronic kidney disease (CKD) and end-stage renal disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost of Type 2 Diabetes Patients with Chronic Kidney Disease Based on Real-World Data: An Observational Population-Based Study in Spain

Usó-Talamantes

González-de-Julián

Díaz-Carnicero

et al. 2021

IJERPH

View full text Add to dashboard Cite

This study analyzed the prevalence, costs and economic impact of chronic kidney disease CKD in patients with T2D in a Spanish Health District using real-world data. Observational cross-sectional study in adult patients with T2D was through data extracted from the information systems of the Valencia Clínico–La Malvarrosa Health District in the year 2015. Patients were stratified with the KDIGO classification for CKD. Additionally, patients were assigned to Clinical Risk Groups (CRGs) according to multimorbidity. Direct costs of primary and specialized care, and medication were estimated. The prevalence of T2D in the database population (n = 28,345) was 10.8% (mean age (SD) = 67.8 years (13.9); 51.5% male). Up to 14.935 patients (52.6%) had data on kidney function. According to the KDIGO classification, 66.2% of the patients were at low risk of CKD, 20.6% at moderately increased risk, 7.9% at high risk, and 5.2% at very high risk. The average healthcare costs associated with these four risk groups were EUR 3437, EUR 4936, EUR 5899 and EUR 7389, respectively. The large number of T2D patients with CKD in the early stages of the disease generated a significant increase in direct healthcare costs. The economic impact could be mitigated by early and comprehensive therapeutic approaches.

show abstract

Prevalencia de diabetes y diabetes oculta en adultos de Castilla-La Mancha

Cited by 9 publications

References 21 publications

Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data

Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data

Health- related quality of life in diabetic people with different vascular risk

Cost of Type 2 Diabetes Patients with Chronic Kidney Disease Based on Real-World Data: An Observational Population-Based Study in Spain

Contact Info

Product

Resources

About